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Abstract
Background: Artemisinin-based combination therapy (ACT) has been recommended for the treatment of
falciparum malaria by the World Health Organization. Though India has already switched to ACT for treating
falciparum malaria, there is need to have multiple options of alternative forms of ACT. A randomized trial was
conducted to assess the safety and efficacy of the fixed dose combination of artesunate-amodiaquine (ASAQ) and
amodiaquine (AQ) for the treatment of uncomplicated falciparum malaria for the first time in India. The study sites
are located in malaria-endemic, chloroquine-resistant areas.
Methods: This was an open label, randomized trial conducted at two sites in India from January 2007 to January
2008. Patients between six months and 60 years of age having Plasmodium falciparum mono-infection were
randomly allocated to ASAQ and AQ arms. The primary endpoint was 28-day PCR-corrected parasitological cure
rate.
Results: Three hundred patients were enrolled at two participating centres, Ranchi, Jharkhand and Rourkela,
Odisha. Two patients in AQ arm had early treatment failure while there was no early treatment failure in ASAQ
arm. Late treatment failures were seen in 13 and 12 patients in ASAQ and AQ arms, respectively. The PCR-corrected
cure rates in intent-to-treat population were 97.51% (94.6-99.1%) in ASAQ and 88.65% (81.3-93.9%) in AQ arms. In
per-protocol population, they were 97.47% (94.2-99.2%) and 88.30% (80-94%) in ASAQ and AQ arms respectively.
Seven serious adverse events (SAEs) were reported in five patients, of which two were reported as related to the
treatment. All SAEs resolved without sequel.
Conclusion: The fixed dose combination of ASAQ was found to be efficacious and safe treatment for P. falciparum
malaria. Amodiaquine also showed acceptable efficacy, making it a suitable partner of artesunate. The combination
could prove to be a viable option in case India opts for fixed dose combination ACT.
Clinical trial registry: ISRCTN84408319
Keywords: Artesunate, Amodiaquine, falciparum malaria, India
Background
The World Health Organization (WHO) has recom-
mended artemisinin-based combination therapy (ACT)
as the treatment for Plasmodium falciparum and many
malaria endemic countries are using it. The combination
of amodiaquine and artesunate, along with four more
combinations, is recommended by WHO for malaria
control programmes [1].
India has switched over to ACT and the National Vec-
tor Borne Disease Control Programme recommends the
use of artesunate + sulphadoxine-pyrimethamine (AS +
SP) for the treatment for falciparum malaria [2]. There
is not much data available on the efficacy of the partner
drug SP, but there is evidence of dhfr and dhps muta-
tions [3] and treatment failure has been reported in
north-eastern states [4]. Further, since the combination
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this provides opportunity for consuming monotherapy.
There is also the issue of dosage in paediatric age
group. This forms the basis of evaluation of different
forms of ACT, which may form an alternative to AS +
SP combination.
The combination artesunate-amodiaquine (ASAQ) has
been extensively studied and good efficacy and tolerabil-
ity has been reported. A systematic review of relevant
studies [5-8] on the treatment of uncomplicated P. falci-
parum malaria conducted over the past 10 years in
Africa showed that amodiaquine (AQ) proved signifi-
cantly more effective than chloroquine in clearing para-
sites, with a tendency for faster clinical recovery. This
difference was also observed in areas with considerable
chloroquine resistance. Further, serious adverse events
have not been reported with curative short-term regi-
men of AQ [9].
A randomized trial was conducted to assess the safety
and efficacy of the fixed dose combination of ASAQ and
AQ alone for treatment of uncomplicated falciparum
malaria for the first time in India. The study sites were
located in malaria-endemic, chloroquine-resistant areas.
Methods
This was an open label, randomized study carried out at
Mahadevi Birla Hospital, Ranchi, Jharkhand and Com-
munity Welfare Society Hospital, Rourkela, Odisha from
January 2007 to January 2008 (Figure 1). Rourkela is
situated in a high malaria-endemic district, Sundargarh
where malaria transmission is perennial with proportion
of P. falciparum cases of about 96%. Ranchi district has
peak malaria season from August to November with
relatively low proportion (50%) of falciparum cases. The
efficacy of chloroquine was 54 to 57% in Sundargarh
and 72% in Ranchi in an earlier study [10]. AS + SP was
the recommended combination for falciparum malaria
in both the study areas during this period.
Patients
T h es t u d yw a sc a r r i e do u ti np a t i e n t sa g e df r o ms i x
months to 60 years, weighing more than 5 kg and hav-
ing P. falciparum mono-infection (asexual parasitaemia
of 1,000-100,000 per μl) and fever ≥37.5°C (99.5°F).
Patients with signs of severe malaria, febrile conditions
due to diseases other than malaria, known severe dis-
ease, history of hypersensitivity to drug(s), positive preg-
nancy test or lactating women, history of anti-malarial
treatment in past 15 days were excluded. Patients were
also excluded from the study if they had anaemia (hae-
moglobin < 7 g/dl), hepatic (alanine aminotransferase/
aspartate aminotransferase ≥ 2.5 ULN) or renal impair-
ment (serum creatinine ≥ 1.2 ULN).
Randomization and treatment
Patients were randomized to one of the two arms in 2:1
ratio; fixed dose combination tablets of ASAQ and AQ
tablets alone using a predetermined randomization list.
Individual, opaque, sealed and sequentially numbered
envelopes were used for randomization. ASAQ was
given once daily orally on days 0, 1 and 2 of the study
according to age group. Two different strengths of the
combination were formulated; paediatric/lower strength
(AS: 25 mg/AQ: 67.5 mg) and adult/higher strength
( A S :1 0 0m g / A Q :2 7 0m g ) .C h i l d r e ni nt h es i xt o1 1
months age group were given one lower strength tablet,
one to five years, two lower strength tablets, six to 13
years one higher strength tablet and those older than 14
years were given two higher strength tablets. AQ tablets
(153 mg base) were administered orally, once daily for
three days. The number of tablets was decided accord-
ing to age and weight with the adult dose being four
tablets on day 0, 1 and three tablets on day 2.
Safety and efficacy assessments
Anti-malarial drug efficacy was assessed by using the
WHO protocol with a 28-day follow up [11]. Participat-
ing patients were hospitalized for a period of three days
and later followed on days 7, 14, 21 and 28 of enrol-
ment. They were also asked to make an unscheduled
visit on any day on which they felt unwell.
The primary endpoint of the study was the PCR -cor-
rected cure rate based on the adequate clinical and
Figure 1 Map of India showing the study sites.
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of parasitaemia, irrespective of patient’s body tempera-
ture, with the patient not meeting any criteria of early
treatment failure or late clinical or parasitological failure
as defined by the WHO [11].
The secondary endpoints included the Parasite Reduc-
tion Ratio, Parasite Clearance Time, Fever Clearance
Time, percent patients without gametocytes on day 28
and proportion of patients with early and late treatment
failure and late parasitological failure.
Laboratory analyses
Blood samples were collected by fingerpick method for
parasitological assessment at enrolment, during admis-
sion and follow up visits. Thick and thin smears were
prepared, Giemsa-stained and examined for parasite
density. This was done by counting the number of asex-
ual parasites per 200 leucocytes in thick blood film.
Parasite density per μl was calculated as (number of
parasites counted × 8,000)/(number of leukocytes
counted). Two qualified microscopists independently
read all of the slides and parasite densities were calcu-
lated by averaging the two counts. Two to three drops
of blood were collected on a chromatography filter
paper no.3 (Whatman, UK) from each patient at inclu-
sion. A second specimen was collected only in the case
of reappearance of parasites as evidenced by a positive
microscopy slide. Genotyping was carried out at NIMR,
Delhi. For differentiating recrudescence from re-infec-
tion, three genetic markers, merozoite surface proteins
(msp1 and msp2) and glutamate rich protein (glurp)
were used [12].
Blood samples were drawn for haematologic (haemo-
globin level, leucocyte count, haematocrit) and biochem-
ical (serum alanine aminotransferase, aspartate
aminotransferase, bilirubin and creatinine) assessments
on day 0, 7, 28 and on the day of recurrent
parasitaemia.
Statistical analysis
This was not a head to head comparative study but
rather a parallel study in which the AQ alone arm acted
as a positive control. Hence, the sample size was esti-
mated using the precision method with a two-sided
alpha of 0.05 and a power of 0.8. On the assumption
that ASAQ will have a cure rate of 95% and a precision
of 5%, the estimated sample size was 73. If a cure rate
of 90% was considered with precision of 5%, the sample
size increased to 138. Hence, it was planned to recruit
about 300 patients; 200 in ASAQ and 100 in AQ arm.
Epi Info 6.04b software was used for these calculations.
Three patient populations were evaluated. The safety
population comprised all patients who were randomized
and received at least one dose of study drug. The safety
analysis and listing was done on safety population. The
intent to treat (ITT) population comprised of all
patients who were randomized, received at least one
dose of study drug and underwent at least one efficacy
assessment. The secondary efficacy analysis was per-
formed on ITT population. Per protocol (PP) population
comprised of all patients who completed the study as
per the protocol. The primary and secondary efficacy
analysis was performed on PP population. Patients who
withdrew from the study or did not appear for the
scheduled visits on or before day 28 were considered as
drop-outs. These patients were part of ITT and safety
population and hence their data were reported.
The primary endpoint of day 28 cure rate was evalu-
ated in both ITT and PP populations. Cure rates were
based on simple proportions. The 95% confidence inter-
val was calculated for both the treatment arms. The sec-
ondary efficacy parameter parasite reduction ratio at 48
hr and Parasite and Fever clearance times were analyzed
in ITT population using Kaplan Meier analysis. Statisti-
cal analyses were done using the software SAS 9.1.3.
Ethical issues
The study was conducted in accordance with the local
laws and regulations including the schedule Y, Indian
Good Clinical Practices, Ethical guidelines on biomedical
research issued by the Indian Council of Medical
Research, International Conference on Harmonization -
Good Clinical Practice (ICH-GCP). The protocol was
reviewed and approved by the Ethics Committees of the
National Institute of Malaria Research, Delhi and Com-
munity Welfare Society Hospital, Rourkela. Written
informed consent was obtained from participants/guar-
dians. In case of an illiterate patient, his/her thumb
impression and signature of an independent witness was
obtained.
Results
Three hundred and twenty seven patients were screened
at the two sites of which, 300 were randomized to the
two treatment arms. The ITT population comprised of
298 subjects, 201 in ASAQ and 97 in AQ arm (Figure
2). The demographic parameters of the patients enrolled
in both the arms are shown as Table 1 and revealed no
significant difference.
In ITT population, the 28-day PCR uncorrected cure
rates were 91.54% (86.8%-95%) and 81.44% (72.3%-
88.6%) in ASAQ and AQ arms respectively. In PP popu-
lation, they were 92.42% (87.8-95.7%) in ASAQ arm and
82.98% (72.8-89.9%) in AQ arm (Table 2).
There were 27 treatment failures (13 in ASAQ and 14
in AQ arm). The PCR analysis showed that six subjects
had new infections (five in ASAQ and one in AQ arm)
and 16 had recrudescence (five in ASAQ and 11 in AQ
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years in ASAQ and AQ arms respectively. The mean
initial parasitaemia was 49065 and 37862 respectively in
ASAQ and AQ arms. Four samples were inconclusive
(three in ASAQ and one in AQ arm), while result could
not be obtained in one sample (AQ arm). The patients
with indeterminate PCR results were classified as recru-
descent infections whereas the new infections were clas-
sified as ‘cured’.
After PCR correction, the cure rates were 97.51%
(94.6-99.1%) and 88.65% (81.3-93.9%) in ITT population.
PCR corrected cure rates in PP population were 97.47%
(94.2-99.2%) in ASAQ and 88.30% (95% CI 80.0-94.0%)
in AQ arm (Table 2). Site wise cure rates in both popu-
lations have been shown in Table 2. Cure rates were
similar in ASAQ at both the sites [97.12% (91.8-99.4%)
at Ranchi and 97.87% (92.5-99.7%) at Rourkela]. Cure
rate of AQ was higher in Ranchi [95.83% (86.7-99.5%)]
as compared to Rourkela [80.43% (66.1-90.6%)] but the
difference was not statistically significant (p > 0.05).
Parasite clearance and resolution of clinical symptoms
The mean parasite densities at enrolment were similar
in both the treatment arms. The median parasite clear-
ance time was one day in ASAQ arm, while it was two
Figure 2 Participant flow.










< 1 year 10
1-12 years 70 26
> 12 years 131 72
Mean Weight (kg) 38.30 42.94
Mean Parasite density (/μl) 26650 29270
Mean(± SD) axillary temperature 100.7 ± 0.91 100.6 ± 0.92
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Page 4 of 8days in AQ arm showing that parasite clearance was sig-
nificantly faster in ASAQ arm (p < 0.0001). The mean
parasite clearance time was 1.5 and 2.1 days in ASAQ
and AQ arms respectively.
The Kaplan Meier estimate of the proportion of apara-
sitaemic patients at 48 hours was 93% (187/201) in
ASAQ arm and 65% (63/97) in AQ arm (Figure 3). The
number of patients completing treatment in ASAQ and
AQ arms was 200 and 94 respectively. Three patients
were withdrawn from the study before 48 hours (one
adverse event in ASAQ and two early treatment failures
in AQ arm).
The Parasite Reduction Ratio was 1,107.5 in ASAQ
arm and 138.8 in AQ arm; the difference was significant
(p = 0.002). The median Fever Clearance Time was
same (one day) in both the treatment arms (Figure 4).
There was no early treatment failure in ASAQ arm
while two (2.1%) patients had early treatment failure in
AQ arm. The proportion of patients with late treatment
failures was 6.5% (13/201) in ASAQ and 12.4% (12/97)
in AQ arms. The proportion of patients with gameto-
cytes at the end of follow-up (day 28) was 1.5% (03/201)
in ASAQ and 2.1% (02/97) in AQ arms. The late clinical
failures, which represented patients from day 4 to 28
with parasitaemia and fever were 4.0% (8/201) in ASAQ
and 5.2% (5/97) in AQ arms. The late parasitological
failures defined as presence of parasitaemia from day 7
to day 28 were 2.5% (05/201) in ASAQ and 7.2% (07/
97) in AQ arms. None of these parameters was statisti-
cally significant in the two treatment arms (p > 0.05).
Protocol deviations
There were in total 10 protocol deviations and five pro-
tocol violations in the study. Of the 10 protocol devia-
tions, nine were related to the study procedures. One
protocol violation was related to the study assessment
when the patient was not available at the correct time
point.
Drug safety
The adverse event (AE) profiles for ASAQ and AQ
treatments were similar in terms of type and frequency
of events and were mostly those expected in malaria
patients. More than half the patients (57.42% in ASAQ
and 59.18% in AQ) experienced AE (Table 3). The dif-
ference between the incidence of AEs in the two treat-
ment arms was not statistically significant (Chi square =
0.084, p > 0.05). The AEs related to the study medica-
tion were six (3.0%) in ASAQ and four (4.1%) in AQ












ASAQ 88.57 (80.9 - 94.0) 94.79 (88.3 - 98.3) 91.54 (86.8 - 95.0)
AQ 88.00 (75.7 - 95.5) 74.47 (59.7 - 86.1) 81.44 (72.3 - 88.6)
PCR corrected
ASAQ 97.14 (91.9 - 99.4) 97.92 (92.7 - 99.7) 97.51 (94.6 - 99.1)





ASAQ 89.42 (81.9 - 94.6) 95.74 (89.5 - 98.8) 92.42 (87.8 - 95.7)
AQ 89.58 (77.3 - 96.5) 76.09 (61.2 - 87.4) 82.99 (73.8 - 89.9)
PCR corrected
ASAQ 97.12 (91.8 - 99.4) 97.87 (92.5 - 99.7) 97.47 (94.2 - 99.2)
AQ 95.83 (86.7 - 99.5) 80.43 (66.1 - 90.6) 88.30 (80.0 - 94.0)
Figure 3 Survival curve (Kaplan Meier plots) of Parasite
Clearance Time (ITT population).
Figure 4 Survival curve (Kaplan Meier plots) of Fever Clearance
Time (ITT population).
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encountered during the study were the manifestations of
the disease: fever, body pain, fatigue and asthenia during
the hospitalized observation period. The more common
AEs related to the medication in both the arms were
the gastrointestinal symptoms: nausea, vomiting and
abdominal pain. Their occurrence was 2.5% and 3.1% in
ASAQ and AQ arms respectively. There were four cases
of vomiting (two each in ASAQ and AQ arms) which
were reported as AEs, assessed by the investigator as
related to the study medication and required medical
intervention. They were resolved within a day following
treatment.
Serious adverse events (SAEs) were reported in five
patients, three (1.5%) in ASAQ and two (2%) in AQ
arm. They were leukocytosis, diarrhoea, vomiting, hyper-
bilirubinaemia and hypersensitivity reaction. In the
ASAQ arm, two SAEs were considered drug related by
investigators. One was angioedema without signs of ana-
phylaxis and another, severe diarrhoea requiring
hospitalization. The SAEs in the AQ arm were unrelated
to the drug. All SAEs resolved without sequelae.
The haematological and biochemical values on day 0
are shown in Table 4. The mean haemoglobin value was
9.8 ± 1.8 g/dL and 10.1 ± 1.9 g/dL in ASAQ and AQ
arms respectively. There was a marginal increase in the
level over 28 day period in both the arms.
There were no significant changes in RBC and WBC
counts over 28 days. There was a marginal decrease in
the levels of total bilirubin, SGOT, SGPT and creatinine
over this period.
Discussion
The study shows that ASAQ fixed dose combination is
efficacious for treatment of falciparum malaria in
India. The PCR-corrected cure rates were 97.47% (95%
CI 94.2 - 99.2%) and 88.3% (95% CI 80.0 - 94.0%) in
ASAQ and AQ arms respectively. The cure rates were
similar in different age groups. The study also supports
t h er o l eo fA Qa sas u i t a b l ep a r t n e ri nA S A Q .T h e
Table 3 Adverse events by treatment groups (safety population)
System organ class ASAQ arm (N = 202)
n (%)
AQ arm (N = 98)
n (%)
Total subjects with at least one AE 114 (56.4) 58 (59.2)
Blood and lymphatic system disorders 23 (11.4) 7 (7.1)
Eye disorders 1 (0.5) 0 (0.0)
Gastrointestinal disorders 56 (27.7) 28 (28.6)
General disorders 53 (26.2) 35 (35.7)
Hepato-biliary disorders 2 (1.0) 2 (2.0)
Immune System disorders 1 (0.5) 0 (0.0)
Infections and Infestations 1 (0.5) 0 (0.0)
Investigation abnormalities 13 (6.4) 3 (3.1)
Metabolism and nutrition disorders 0 (0.0) 1 (1.0)
Musculoskeletal and connective tissue disorders 2 (1.0) 5 (5.1)
Nervous system disorders 18 (8.9) 14 (14.3)
Respiratory, thoracic and mediastinal disorders 5 (2.5) 2 (2.0)
Skin and subcutaneous tissue disorders 0 (0.0) 1 (1.0)
Vascular disorders 3 (1.5) 2 (2.0)
Table 4 Biochemical characteristics of Patients on Day 0, 7, and 28
ASAQ AQ
D0 D7 D28 D0 D7 D28
Haemoglobin (g/dL) 9.8 ± 1.8 10 ± 1.52 11 ± 1.41 10.1 ± 1.94 10.4 ± 1.94 11.2 ± 1.51
RBC (million/mm
3) 4.6 ± 0.67 4.6 ± 0.62 5.1 ± 0.6 4.7 ± 0.71 4.8 ± 0.66 5.1 ± 0.65
WBC (/mm
3) 6851 ± 2043.49 7776.4 ± 1644.18 7384.2 ± 1382.73 6934.7 ± 1791.57 7537.6 ± 1678.31 7444.6 ± 1203.77
Total Bilirubin (iu/L) 1.1 ± 0.63 0.6 ± 0.24 0.5 ± 0.23 1.2 ± 0.67 0.6 ± 0.25 0.5 ± 0.29
SGOT (iu/L) 32.2 ± 11.34 28.3 ± 8.48 24.8 ± 10.73 31.4 ± 9.18 26.8 ± 5.67 24.4 ± 7
SGPT (iu/L) 26 ± 11.23 25.2 ± 13.59 19.5 ± 8.29 24.8 ± 10.92 23.3 ± 8.81 20.1 ± 9.39
Creatinine (iu/L) 0.9 ± 0.16 0.8 ± 0.14 0.8 ± 0.11 0.9 ± 0.16 0.9 ± 0.16 0.8 ± 0.13
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ITT population. Further, they were similar at both
the sites. The combination has the advantage of once
daily administration, thus increasing compliance. The
r e s u l t so ft h i ss t u d ya r ei nl i n ew i t ht h er e s u l t s
obtained in Cameroon, Madagascar, Mali [13], Senegal
[13,14], and Ivory Coast [14] and Myanmar [15]. A
recent study carried out in Senegal has shown the uti-
lity of ASAQ in recurrent uncomplicated falciparum
malaria [16]
Currently, AS + SP has been recommended by the
National Vector Borne Disease Control Programme in
India. The combination is efficacious [17] but treatment
failures have been reported with the partner drug SP
[4]. There is also evidence of dhfr and dhps mutations
especially in the north-east [3]. Further, since the com-
bination is available as blister pack, compliance may be
poor and also provides opportunity of consuming arte-
sunate mono-therapy. Hence, there is need to shift to
fixed dose ACT. ASAQ fixed dose combination could
be one of the options since it is safe, efficacious and the
partner drug AQ also has an acceptable efficacy at least
in the study areas. Amodiaquine is known to have
cross-resistance with chloroquine. However, studies
h a v es h o w nA S A Qt ob ee f f e c t i v ee v e ni na r e a sw i t h
chloroquine resistance [18]. Even the present study was
carried out in areas with chloroquine resistance. The
utility of ASAQ has also been demonstrated in home
management of malaria [19] and also as intermittent
preventive therapy in children [20]. The combination
can also be useful for vivax malaria and clinically sus-
pected malaria.
According to WHO, to qualify as ACT the combina-
tion should also have independent anti-malarial activity
[1]. The study showed that AQ had PCR-corrected effi-
cacy of 88.3% (80.0 - 90.6%). The combination is also
one of the five WHO prequalified forms of ACT.
Fever was the most common AE but was considered
unrelated to the study medication and caused by malaria
itself. In the related subgroup, nausea and vomiting were
t h em o r ec o m m o nA E s ,a n dt h e ym a yi n d i c a t et h eg a s -
tric irritation caused by the study medication.
The drug has been registered for marketing in India
on the basis of results of this study.
Conclusion
Fixed dose combination ASAQ proved to be an effica-
cious and safe treatment for falciparum malaria in both
the study areas. The study also showed that the partner
drug, AQ was effective in the study areas, making it a
suitable partner of artesunate. The combination could
p r o v et ob eo n eo ft h ev i a b l eo p t i o n si nc a s eI n d i ao p t s
for fixed-dose combination ACT.
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